Vensica Medical, a urology therapeutics company, has successfully closed an $11 million funding round to support Phase 2 clinical trials in the United States and Europe for its needle-free treatment of overactive bladder (OAB). The innovative approach uses botulinum toxin A (Xeomin®) delivered via a proprietary, needle-free device, potentially transforming the standard of care for OAB.
The investment round was led by Israel Biotech Fund (IBF), with strategic partners Merz, a global neurotoxin player, and Laborie, a urology medical device company, also participating. This financial backing will enable Vensica to progress its mission of providing a minimally invasive and effective solution for individuals suffering from OAB.
Needle-Free Delivery System
Vensica's technology employs a needle-free drug delivery system to administer Xeomin® directly to the bladder wall. This method is designed to offer patients a less invasive and more comfortable treatment option compared to traditional injections. The company envisions its needle-free drug delivery system as a platform for treating various bladder conditions.
Avner Geva, CEO of Vensica, stated, "We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment. This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it."
Strategic Partnership with Merz
As part of its strategic alliance with Merz, Vensica has secured exclusive rights to Xeomin® for needle-free therapeutic applications in several urologic indications. Vensica will also benefit from Merz's clinical development support. This collaboration marks a significant advancement in Vensica's objective of delivering next-generation urology treatments.
About Overactive Bladder (OAB)
Overactive bladder is a common condition characterized by a frequent and urgent need to urinate, which can significantly impact a person's quality of life. Current treatments include lifestyle changes, medications, and, in some cases, more invasive procedures like botulinum toxin injections directly into the bladder muscle. Vensica's needle-free approach aims to reduce the invasiveness and improve patient comfort compared to traditional methods.
